Background: Most clinical research investigated prognostic biomarkers for their ability to predict cardiovascular events or mortality. It is unknown whether biomarkers allow prediction of quality of life (QoL) after survival of the acute event. Herein, we investigated the prognostic potential of well-established inflammatory/cardiovascular blood biomarkers including white blood cells (WBC), C-reactive protein (CRP), procalcitonin (PCT), pro-adrenomedullin (proADM) and pro-atrial natriuretic peptide (proANP) in regard to a decline in QoL in a well-defined cohort of patients with community-acquired pneumonia (CAP). Methods: Within this secondary analysis including 753 patients with a final inpatient diagnosis of CAP from a
Introduction
Community-acquired pneumonia (CAP) is the leading cause of death from infectious disease [1] , and is responsible for high mortality, morbidity, and costs worldwide [2, 3] . Pneumonia is not only associated with high shortterm mortality [4, 5] , but even more substantial longterm mortality rates in patients surviving an initial CAP episode, as compared to the general population and to patients suffering from other infections, respectively [6] [7] [8] [9] [10] [11] . In addition, CAP is associated with a higher short-and long-term risk of adverse cardiovascular events compared to controls [12] , and pneumonia has lately been proposed to be an independent cardiovascular risk factor [12] . Importantly, quality of life (QoL) in individuals surviving a CAP episode has become an important health care indicator and should also be considered when looking at CAP outcomes.
Much research has focused on short-and long-term outcome prognostication in the CAP patient population. This may help to better guide initial site-of-care decisions, and optimize discharge strategies and post-discharge outpatient management. In addition to clinical risk scores, such as the pneumonia severity index (PSI) [13] , several inflammatory and/or cardiovascular blood biomarkers such as white blood cells (WBC), C-reactive protein (CRP), procalcitonin (PCT), pro-adrenomedullin (proADM), as well as pro-atrial natriuretic peptide (proANP) have been found helpful for risk prediction [6, [14] [15] [16] [17] [18] [19] [20] . Particularly, proADM [9, 6, [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] , proANP [9, 6, 25, [31] [32] [33] and PCT [10, 22, 25, 31, [34] [35] [36] have been associated with risk for shortand long-term all-cause mortality as well as other adverse outcomes, such as severity of illness, admission to the intensive care unit (ICU), and disease-specific complications. Yet, there is insufficient evidence whether these clinical parameters and blood biomarkers are also helpful in predicting more subjective QoL outcomes: mens sana in corpore sano?
Herein, our aim was to study prognostic biomarkers for their ability to predict a decline in QoL in a welldefined cohort of CAP patients. The early and accurate identification of patients being at risk for a decline in QoL after an index hospitalization for CAP may optimize patient satisfaction, inhospital and discharge management, and improve our pathophysiological understanding of this disease.
Materials and methods

Aims
The prognostic accuracy of previously published inflammatory and cardiovascular blood biomarkers was investigated to predict a decline in QoL in the short-term (30 days) and long-term (6 years).
Study design and setting
This is a secondary analysis from a prospective randomized-controlled, multi-center trial performed at six Swiss secondary or tertiary care centers between October 2006 and March 2008 [37] . A detailed study protocol of the initial trial has been published elsewhere [38] . Briefly, from a total of 1825 potential patients admitted to the emergency department (ED), 925 subjects with a final inpatient diagnosis of CAP were included on admission. The aim of the initial prospective, multicenter, randomized-controlled trial was to assess the efficacy and safety of PCT guided antibiotic therapy compared to standard guidelines without using PCT data [39] [40] [41] in hospitalized patients with lower respiratory tract infections [37] .
The study protocol was approved by the Ethics Committee of the University of Basel as well as by all Local Ethics Committees, written informed consent was provided by all participants for the initial trial, including agreement to use their data anonymized in secondary analyses.
Selection and assessment of participants
Inclusion criteria were age > 18 years and final diagnosis of CAP with an infiltrate on chest X-ray [37, 40, 42] . Exclusion cirteria were language restriction or dementia precluding patients from providing written informed consent, a terminal condition, intravenous drug abuse as well as hospital-acquired pneumonia. Additionally, patients were excluded due to severe immunosuppression or longterm antibiotic therapy on admission, while being a recipient of corticosteroids or short-term antibiotic pretreatment were allowed.
Patient assessment included clinical and biochemical evaluation upon admission to the ED and throughout the period of hospitalization. The standardized baseline characteristics comprised medical history, comorbidities (identified either through patient selfreport or medical chart review), vital signs, laboratory values, chest X-ray and medication. To assess disease severity, the PSI [13] and the confusion, urea, respiratory rate, blood pressure, age > 65 years (Curb-65 score) [40] -validated risk assessment tools to categorize CAP patients into different risk classes -were calculated upon ED admission. Discharge decision concerning patients enrolled in the study was completely left to the treating physicians without interference of the study team.
For the present analysis, all of initially included 925 patients with a final inpatient diagnosis of CAP were eligible for analysis, if they had available information on admission blood biomarker levels and if they survived until the follow-up period for completion of the QoL assessment performed at 30 days and 6 years. After exclusion of 50 non-survivors (5%) at day 30 and 417 non-survivors (45%) at 6 years, as well as 122 (13%) and 159 (17%) survivors with missing information on the QoL assessment, the final cohort consists of 753 of 925 patients (81%) for the day 30 analysis, and 349 of 925 patients (38%) for the 6-year analysis.
Analysis of blood biomarkers
Within the initial trial, blood samples for later measurement of different biomarkers were collected upon admission to the ED and throughout the hospitalization period. In the present analysis, we focused on five inflammatory and/or cardiovascular markers (WBC, CRP, PCT, proADM and proANP). Determination of WBC, CRP and PCT was done during clinical routine, while proADM and proANP were determined by batch analysis only after study completion. For quantification of PCT levels, an automated, sensitive assay (KRYP-TOR PCT; Thermo Scientific Biomarkers [formerly BRAHMS AG], [16, 25] 20 [16, 25] 20 [16, 26] 0.12 20 [16, 24] 20 [16, 24] 20 [16, 24] (28) 8.0% (16) 8.1% (12) 0.96
Any problem with usual activities 26.7% (201) 27.0% (144) 26.0% (57) 0.79
12.0% (42) 11.4% (23) 12.8% (19) Combined model is adjusted for baseline values of each dimension of the EQ-5D descriptive system comprising mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Henningsdorf, Germany) was used, showing a lower detection limit of 0.02 μg/L and a functional sensitivity of 0.06 μg/L. Measurements of proADM plasma levels were performed by a sandwich immunoassay with a lower detection limit of 0.08 nmol/L [43, 44] . Determination of proANP plasma levels was performed by another sandwich immunoassay (BRAHMS AG, Henningsdorf/Berlin, Germany) with a lower detection limit of 4.3 pmol/L and a functional sensitivity of 11 pmol/L, as previously described [45] .
Patient outcomes
The primary endpoint of this study was a decline in QoL from hospital admission (baseline) to day 30 and after 6 years. For this purpose, QoL was measured with the EQ-5D health questionnaire as recommended [46] [47] [48] in the ED on the day of admission -assessing QoL of the past 7 days -and by telephone interviews during the follow-up. The EQ-5D comprises the five-item tool EQ-5D self-classifier , a descriptive system, which assesses the health-related QoL along the following five dimensions: 'mobility', 'self-care', 'usual activities', 'pain/ discomfort' and 'anxiety/depression'. Each domain is expressed by three severity levels. Importantly, the EQ-5D instrument provides calculation of a weighted country-specific single index value [49] , considered as primary endpoint. It additionally includes the EQ VAS recording the patients' self-rated health state on a vertical scale as a quantitative measurement.
Secondary endpoints were defined as a decline in the different 5 dimensions of EQ-5D and in the self-reported health state using the EQ VAS after 30 days and 6 years post-discharge. baseline values of each dimension of the EQ-5D descriptive system comprising mobility, self-care, usual activities, pain/discomfort, anxiety/depression.
To ascertain outcomes, blinded medical students performed structured phone interviews at 30 days after enrolment as well as after a median of 6.1 years [interquartile range (IQR) 5.6-6.5]. If patients or their family members could not be contacted, the treating primary care physicians were called.
Statistical analyses
Statistical analyses were conducted using STATA 12.1 (Stata Corp, College Station, TX, USA). A p-Value < 0.05 indicated statistical significance. Description of the study population was performed by descriptive statistics including medians with IQRs to express continuous variables, and frequencies (percentages) for categorical variables. Wilcoxon rank-sum test was used for two-group comparison, whereas frequency comparison was done by chisquare test.
Univariate and multivariate logistic regression analyses were performed to assess the association of blood biomarker values with a decline in QoL from baseline to day 30 and after 6 years. Results are reported as odds ratios (ORs) with 95% confidence intervals (95% CIs) and significance levels calculated by chi-square test. Models were adjusted for either age and gender, important comorbidities (coronary heart disease, cerebrovascular insult, chronic renal failure, neoplastic disease) or baseline QoL (including each dimension of the EQ-5D descriptive system into the model). Before entering regression models, blood biomarker levels were log-transformed due to a skewed distribution.
Results
Baseline characteristics
Baseline characteristics of the entire cohort and stratified by the primary endpoint, i.e. the change in QoL at 30 days and 6 years, are presented in Table 1 . The study included 753 patients for the analysis after 30 days and 349 after 6 years. A total of 29% of patients showed a decline in QoL at 30 days and 42% after 6 years. Median age of the entire cohort was 72 years, and patients had a high burden of comorbidities with 19% (142) of patients suffering from coronary heart disease, 16% (121) congestive heart failure, 20% (151) chronic renal failure, 17% (126) diabetes mellitus and 12% (93) neoplastic disease.
Patients with a decline in QoL had higher age as compared to individuals with no decline at both time points. There was no difference in terms of gender and comorbidities except for chronic renal failure (26% vs. 18%) and neoplastic disease (12% vs. 5%). In regard to biomarkers, discharge values of proADM and both admission and discharge levels of proANP were increased in patients with a Associations between blood biomarker levels and quality of life Table 2 shows the results of uni-and multivariate logistic regression analyses assessing associations of initial blood biomarker values and a decline in QoL after 30 days and 6 years. In the adjusted model including adjustment for baseline QoL, significant associations of initial proADM and proANP levels with a decline in the weighted EQ-5D index after a 30-day follow-up period was found with ORs of 2.0 ([95% CI 1. In a secondary analysis, we also focused on a decline in the different QoL dimensions as well as a decline in VAS (Tables 3 and 4) . Regression analyses demonstrated, that proADM and proANP levels were significantly associated with worsening in 'mobility', 'self-care' and 'usual activities' over both 30 days and 6 years. This association remained robust after adjustment for baseline QoL ( Table 3 ). As presented in Table 4 , only proANP was associated with a decline in the 'anxiety/depression' dimension, while proADM was not. In addition, no associations with measured biomarker levels were found for a decline in 'pain/discomfort' and the VAS after model adjustment.
We also calculated area under the receiver operating curve (AUC) of the different markers and decline of QoL (Tables 2-4) , as well as prognostic accuracy measures including sensitivities, specificities, negative and positive predictive values. For proADM, these measures showed at an optimal cut-off of 1.33 nmol/L a sensitivity of 44% and specificity of 62% with positive and negative predictive values of 33% and 73%, respectively. At the optimal cut-off of 168 nmol/L of proANP, the sensitivity was 61% with a specificity of 59% and positive and negative predictive values of 39% and 78%.
To further illustrate these findings, results of adjusted logistic regression models are presented in forest plots (Figures 1-4) , demonstrating blood biomarker values according to the change in QoL.
We also investigated discharge as well as high peak levels of the respective blood biomarkers, and their association with QoL, showing similar results (data not shown). Odds ratios > 1 reflect a positive association between biomarker levels and worsening of QoL. Models are adjusted for baseline values of each dimension of the EQ-5D descriptive system comprising mobility, self-care, usual activities, pain/discomfort, anxiety/depression. CAP, community-acquired pneumonia; CI, confidence interval; CRP, C-reactive protein; EQ-5D, EuroQol 5 dimensions; OR, odds ratio; PCT, procalcitonin; ProADM, proadrenomedullin; ProANP, pro-atrial natriuretic peptide; QoL, quality of life; WBC, white blood cell count.
Discussion
The findings of this first study investigating the ability of circulating inflammatory and cardiovascular biomarker levels to predict a decline in QoL in CAP patients are two-fold. First, proADM and proANP predicted worsening in the weighted QoL index over 30 days and 6 years in patients hospitalized for CAP. Other prognostic inflammatory markers including WBC, CRP and PCT did not show any significant association. Second, regarding the different dimensions of QoL as assessed with the EQ-5D descriptive system, changes in 'mobility', 'self-care' and 'usual activities' were strongly associated with high levels of proADM and proANP in the short-and long-term, whereas impairment in the domain 'pain/discomfort' and the VAS showed no association after model adjustment.
Multiple studies have demonstrated that suffering from CAP is an indicator of poor prognosis with impaired short-and long-term outcome [4] [5] [6] [7] [8] [9] [10] [11] . CAP per se is associated with an increased rate of adverse cardiovascular events [12] . On the one hand comorbidities such as cardiac disease and malignancy might be the reasons for this poor prognosis, on the other hand, pneumonia itself has recently been proposed to be an independent cardiovascular risk predictor [12] . Thereby inflammatory host response might act as a relevant contributor by modifying the ratio between prothrombotic and antithrombotic factors. Due to this hard endpoints, it is crucial to pay attention to patients' subjective QoL in time following a CAP episode. Early identification of those being at risk for a decline in QoL could lead to improved health state by providing individual medical resources such as physical therapy, prescription of a walking stick/frame, registration at a retirement or nursing home as well as, e.g. psychological support even at an early stage of disease. This in turn might result in a reduction of rehospitalization rates and outpatient visits, potentially lowering health care costs. The present analysis of a large, well-characterized cohort provides novel insights into the prediction of patient-specific QoL outcomes in hospitalized CAP and is thus worth mentioning.
Based on several clinical observational studies, circulating proADM and proANP have lately emerged as useful prognostic tools regarding all-cause mortality, ICU admission, severity of illness and disease-specific complications in CAP [9, 6, 25, [31] [32] [33] . The present analysis expands these findings by demonstrating a relevant correlation between high proADM and proANP levels and future decline in QoL in CAP patients. Since proADM acts as an immune regulatory peptide [50] [51] [52] [53] [54] as well as a potent vasodilatator [55, 56] , and is upregulated due to hypoxia, inflammatory conditions, bacterial products and shear stress [51, 52, [57] [58] [59] [60] , it is tempting to speculate that the grade of respiratory insufficiency and the acute inflammatory host response during a CAP episode might have a relevant impact on patients' QoL in the short-and long-term. Moreover, considering proADM as a cardiovascular peptide [55, 56] , high circulating levels might indicate a chronic condition of vascular stress based on endothelial damage, again potentially resulting in future health state impairment. ANP, a member of the family of natriuretic peptides, regulates natriuresis and diuresis, and lowers systemic blood pressure [61, 62] ; additionally, increased proANP concentrations have been observed in patients suffering from severe infections [63] . Thus, proADM and proANP may mirror both, the acute inflammatory response reflecting the actual state of disease, and the concomitance of cardiovascular comorbidities as a static component. It must be emphasized that results of logistic regression analyses according to the change in the EQ-5D index were similar for admission and discharge proADM and proANP levels, assuming discharge values to basically represent the chronic state of expression.
Considering the lower predictive ability of proADM and proANP according to 'pain/discomfort' and 'anxiety/ depression' compared to the other documented QoL domains, one could hypothesize that the former two dimensions underly other pathophysiological mechanisms than the categories 'mobility', 'selfcare' and 'usual activities'. It is likely, that discomfort and feelings of being depressed or anxious are rather influenced by psychological and social factors, than by the state of inflammation or concomitant cardiovascular disease. This assumption needs verification in future studies. On the other hand, it Odds ratios > 1 reflect a positive association between biomarker levels and worsening of QoL. Models are adjusted for baseline values of each dimension of the EQ-5D descriptive system comprising mobility, self-care, usual activities, pain/discomfort, anxiety/depression. CAP, community-acquired pneumonia; CI, confidence interval; CRP, C-reactive protein; EQ-5D, EuroQol 5 dimensions; OR, odds ratio; PCT, procalcitonin; ProADM, proadrenomedullin; ProANP, pro-atrial natriuretic peptide; QoL, quality of life; WBC, white blood cell count.
should be taken into account, that pain and discomfort as well as anxiety and depression might exhibit a bigger variety during the day because of diurnal mood fluctuation, making it difficult to collect data homogenously. Otherwise, we assume patients' self-assessment in terms of current 'mobility', 'selfcare and 'usual activities' to be more stable in the daytime and thus easier to quantify. Importantly, in adjusted regression models none of the analyzed blood biomarkers correlated with self-reported health-state by VAS in the months and years after a CAP Odds ratios > 1 reflect a positive association between biomarker levels and worsening of QoL. Models are adjusted for baseline values of each dimension of the EQ-5D descriptive system comprising mobility, self-care, usual activities, pain/discomfort, anxiety/depression. CAP, community-acquired pneumonia; CI, confidence interval; CRP, C-reactive protein; EQ-5D, EuroQol 5 dimensions; OR, odds ratio; PCT, procalcitonin; ProADM, proadrenomedullin; ProANP, pro-atrial natriuretic peptide; QoL, quality of life; WBC, white blood cell count.
episode. Again, other potential predictors as well as the probable fluctuation intraday might have had an influence on the respective outcome.
The main strengths of this study include the welldefined and characterized cohort of patients hospitalized for CAP, the long follow-up period of 6 years and the thorough and highly accurate biomarker measurement methods. The large sample size and the high number of primary endpoints in the short-and long-term (29% and 42%, respectively) lead to high statistical power, which in turn allows detecting even small differences in biomarker levels. Nevertheless, the following limitations require consideration: First, the present study is a secondary analysis and therefore rather hypothesis generating. Second, the initial trial was conducted in different secondary and tertiary care hospitals in Switzerland, and thus results may not be applicable to other settings such as primary or intensive care, and other countries. Third, due to the exclusion of non-survivors, we assume the herein analyzed cohort to comprise healthier subjects as compared to the CAP population usually treated in EDs. This suggestion is in line with the observation that CAP non-survivors enrolled in the initial trial displayed a significantly higher concomitance of comorbidities and showed higher PSI values compared to survivors [6] . Thus, the present results might not unconditionally be generalizable to the severely ill. Due to the high number of non-survivors we did not do an analysis with imputation of the worst QoL valuenamely death -for these patients as the analysis would have been strongly driven by mortality. In addition, within our analysis we focused specifically on patients suffering from CAP; further studies are required to validate these findings for other medical and surgical patient populations. Also, our baseline QoL may has been affected by the acute medical situation in the ED and may differ thus from later measurements using telephone interviews. Finally, since this was an observational study, it is only hypothesis generating and correlation does not imply causality.
Conclusions
In conclusion, proADM and proANP levels allowed accurate short-and long-term prognostication regarding the change in QoL in hospitalized CAP. Importantly, proADM and proANP most accurately discriminate a decline in QoL as compared to WBC, CRP and PCT levels. An improved risk stratification in CAP regarding the change in QoL with an early risk-based, 'personalized' deployment of medical resources could potentially improve subsequent health state, reduce rehospitalization rates, decrease outpatient consultations, and may in turn contribute to a more costeffective patient management.
